The USA's Quinnova Pharmaceuticals has launched Salvax (hydrating topical foam) Rx for the treatment of hyperkeratotic conditions such as psoriasis, keratosis pilaris and xerosis.
Salvax contains 6% salicylic acid, a potent keratolytic agent, formulated in a water-lipid based foam. The product utilizes Quinnova's patented Proderm Technology, containing a unique combination of physiological lipids, dimethicone and glycerin which together help to restore the skin barrier, hydrate and protect the skin, in addition to having anti-inflammatory properties.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze